By Peptide Specialty…
To get in touch with Peptide Specialty Laboratories GmbH, simply fill out the form below.
Subscribe to Supplier
PSL Peptide Specialist Laboratories bringing synthesis insights to PTF 2022 Basel
Heidelberg, Germany: – Custom and modified peptide synthesis experts PSL Peptide Specialty Laboratories will be an active presence at the Swiss Chemical Society’s upcoming Peptide Therapeutics Forum in Basel, Switzerland.
It will use the event to share knowledge and find partners for its leading edge continuous synthesis and other technology platforms.
Leading edge platforms
PSL will be represented at the forum at University Hospital of Basel by its Managing Director, Dr. Adrian Glas, who explained that the event was a valuable knowledge sharing and networking opportunity for PSL.
Dr. Glas will also be ready to talk to prospective research and development partners about PSL’s extensive portfolio of capabilities that include leading-edge parallel and microwave-assisted peptide synthesis, as well as PSL’s specially developed continuous-flow synthesizer platform.
Extracting maximum value
“Peptides and oligos have already had significant impact as therapeutics and there is still a great potential to explored,” said Dr. Glas.
“We at PSL want to help our customers to derive maximum value and benefit from these exciting technologies. The Peptide Therapeutics Forum 2022 in Basel will give us a great platform to hear about the latest discoveries and trends, as well as meeting old and new friends,” Dr. Glas added.
About PSL Peptide Specialty Laboratories
Heidelberg-based PSL Peptide Specialty Laboratories specializes in synthesizing custom peptides, modified peptides as peptidomimetics and tailor-made peptide-specific antibodies.
PSL’s core expertise is in developing customized peptides varying in length up to 100 amino acids, individualized to customer requirements. These peptides can be further modified with modified amino acids (methylated, phosphorylated, sugar-modified, D-amino acids, stable isotopes etc.) through acetylation, placing amide at C-terminus and using peptide-protein conjugates (KLH, OVA, BSA, Diphtheria toxoid).
The laboratory develops and produces a range of customized synthetic peptides, bio conjugates and peptide-specific antibodies for research institutes, universities and pharma companies. It also synthesizes peptides as substrates for enzymes or performs modifications of peptides with specific properties that cannot be created naturally, mainly for use in drug research and also to produce complete immunization services.
Founded in 2000, PSL is a private-owned company. Further information at: https://www.peptid.de/en/homepage/
About Peptide Therapeutics Forum 2022
First staged in 2019, the Swiss Chemical Society hosted Peptide Therapeutics Forum aims to provide an innovative platform for knowledge exchange on the various aspects of peptide-related drug development.
The 2022 Forum, reverting back to a fully face-to face format for the first time since its inception, will be a two-day event opening August 25 at the University Hospital of Basel’s ZLF Center for Teaching and Research.
There will be four forums exploring different aspects of therapeutic peptide and oligomer development, including important new insights from drug discovery and case studies for successful development candidates.
The event is organized by the Swiss Chemical Society with further information at: https://ptf22.scg.ch